These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28627792)

  • 1. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
    Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
    Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors.
    Timbergen MJM; Boers R; Vriends ALM; Boers J; van IJcken WFJ; Lavrijsen M; Grünhagen DJ; Verhoef C; Sleijfer S; Smits R; Gribnau J; Wiemer EAC
    Front Oncol; 2020; 10():565031. PubMed ID: 33194643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
    Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
    Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTNNB1 Mutations and Estrogen Receptor Expression in Neuromuscular Choristoma and Its Associated Fibromatosis.
    Carter JM; Howe BM; Hawse JR; Giannini C; Spinner RJ; Fritchie KJ
    Am J Surg Pathol; 2016 Oct; 40(10):1368-74. PubMed ID: 27259010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis.
    Bo N; Wang D; Wu B; Chen L; Ruixue Ma
    Pediatr Dev Pathol; 2012; 15(3):173-8. PubMed ID: 21323417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
    Carrillo-García J; Hindi N; Conceicao M; Sala MÁ; Ugalde A; López-Pousa A; Bagué S; Sevilla I; Vicioso L; Ramos R; Martínez-Trufero J; Gómez Mateo MC; Cruz J; Hernández-León CN; Redondo A; Mendiola M; García JM; Hernández JE; Álvarez R; Agra C; de Juan-Ferré A; Valverde C; Cano JM; Sande LM; Pérez-Fidalgo JA; Lavernia J; Marcilla D; Gutiérrez A; Moura DS; Martín-Broto J
    Eur J Cancer; 2024 Sep; 209():114270. PubMed ID: 39142211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
    Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
    Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.